Just saw that Agios got PYRUKYND approved in the UAE for thalassemia treatment. Pretty interesting move - it's the only medicine approved there for this patient population, which is a big deal for that thalassemia profile. They partnered with NewBridge Pharmaceuticals back in 2024 to handle the Gulf region rollout. Already approved in the US and Europe under different names (AQVESME in the US). The approval was based on those Phase 3 ENERGIZE trials. Feels like biotech is finally making progress on rare blood disorders. Wonder how the thalassemia market will respond to this being the only option available there?

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin